Pluriomics receives a €3.2M grant under the Horizon 2020 SME instrument programme to advance cardiovascular drug discovery

Leiden, June 16, 2016 – Pluriomics, an emerging Dutch/Belgian biotechnology company whose mission is to deliver innovative human cardiomyocyte assays for use in drug discovery & development, today announced it was awarded a prestigious EU SME instrument grant. This grant gives Pluriomics the opportunity to advance cardiovascular drug discovery, in order to reduce the development […]

READ MORE read more

Pluriomics in €2M alliance to develop in vitro heart failure models

Leiden, The Netherlands, May 2016: Pluriomics, a Dutch biotech company focusing on the development of fully functional human stem cell-based assay systems, today announced that it will lead a €2.0 million Eurostars consortium for the development of a novel in vitro organ-on-a-chip heart failure model for drug discovery and development. In this 3 years project, […]

READ MORE read more

News archive

MipTec – BLSW 2016

Date: September 20-22, 2016 Location: Basel, Switzerland Pluriomics will be present at MipTec 2016 during the Basel Life Science Week (BLSW) at September 20th. On Tuesday, September 20th (16:15 – 16:45) Dr. Marijn Vlaming, VP Technology at Pluriomics, will give a talk entitled “Assessment of anti-cancer drug induced cardiotoxicity in human induced pluripotent stem cell (hiPSC) […]

READ MORE read more

ISSCR 2016 Annual Meeting

Date: June 22 – June 25Location: San Francisco, CA Pluriomics will attend the ISSCR Annual Meeting in San Francisco, CA Pluriomics will attend the ISSCR 2016 annual meeting and will present their poster entitled “Improved functional maturation of human induced pluripotent stem cell (hiPSC) derived cardiomyocytes in vitro using well-defined differentiation and maturation media”. Don’t […]

READ MORE read more

Events archive

About us

Pluriomics develops and commercializes fully functional, human iPSC-derived cardiomyocytes and provides high quality services for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening.

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human iPSC derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics combines Pluricyte® Cardiomyocytes with innovative technologies to develop in-house cell-based assays with the objective to improve drug safety and efficacy screening.

Read more

Pluricyte® Cardiomyocyte Kit

Pluricyte® Cardiomyocyte Kit is developed and manufactured for use in
drug discovery and development. The kit includes both
 Pluricyte® Cardiomyocytes and Pluricyte® Cardiomyocyte Medium (serum-free).

iView product information

Pluriomics' products

Our solutions